La dispnea nell'anziano - Associazione Geriatri Extraospedalieri
La dispnea nell'anziano - Associazione Geriatri Extraospedalieri
La dispnea nell'anziano - Associazione Geriatri Extraospedalieri
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
n = 7,800<br />
Telmisartan<br />
80 mg/day‡ +<br />
placebo<br />
Screening<br />
Randomisation (n=23,400) *<br />
n = 7,800<br />
Ramipril<br />
10 mg/day +<br />
placebo<br />
Follow-up at 6 weeks<br />
Follow-up at<br />
6 months for 5.5 years<br />
*planned<br />
Actual = 25,620<br />
ONTARGET ® study design<br />
n = 7,800<br />
Telmisartan<br />
80 mg/day +<br />
ramipril<br />
10mg/day<br />
‡ Maximum approved dose for the treatment of hypertension<br />
5.5 Years<br />
Primary endpoints<br />
Composite CV endpoint<br />
– Cardiovascular mortality<br />
– Non-fatal myocardial<br />
infarction<br />
– Hospitalisation for<br />
congestive heart failure<br />
– Non-fatal stroke<br />
Teo K, et al. Am Heart J 2004;148:52–61; The ONTARGET Investigators.<br />
N Engl J Med 2008;358:1547–1559
Change language